
AI-generated summary
Daewoong Pharmaceutical has been expanding its research base for stem cells and immune and gene treatments for the past 10 years, centered on the Yongin Bio Center in Gyeonggi Province.
Daewoong Pharmaceutical [069620] announced on the 29th that it had established a new โadvanced biopharmaceutical manufacturing plantโ in Songdo, Incheon.
The bio manufacturing plant is located on the Yonsei University International Campus in Songdo, and has a global standard level sterile manufacturing and quality control system to produce stem cell and immune cell products for clinical research.
Daewoong Pharmaceutical plans to complete legal permission for manufacturing and processing advanced biopharmaceuticals and operate the facility within the year.
Daewoong Pharmaceutical explained that it promoted the construction of the Songdo manufacturing plant in order to connect the accumulated research to the clinical stage and secure a stable production base for advanced biomaterials needed for clinical research.
In addition, the plan is to utilize the research and medical infrastructure owned by the Songdo Bio Cluster to expand open innovation cooperation with local universities, research institutes, and medical institutions to build an ecosystem where research results can lead to clinical trials and treatment.
About 30 officials from related organizations, including the Ministry of Health and Welfare, Incheon Free Economic Zone Authority, and Yonsei University, attended the opening ceremony held on the 28th.
Attendees viewed the manufacturing facility and discussed ways to cooperate to link bio research and clinical trials.
Daewoong Pharmaceutical has been expanding its research base for stem cells and immune and gene treatments for the past 10 years, centered on the Yongin Bio Center in Gyeonggi Province.
In the future, we plan to expand the global bio network encompassing research, clinical trials, and production by linking domestic bases with overseas bases such as Indonesia.
Park Seong-soo, CEO of Daewoong Pharmaceutical, said, "Songdo Advanced Biopharmaceutical Manufacturing Center will be a key base for quickly connecting Daewoong Pharmaceutical's advanced bio research results to clinical trials. Based on the clinical research infrastructure connecting Yongin and Songdo, we will grow together with the bio ecosystem by collaborating with excellent researchers and base medical institutions."
AI outlook โ possibilities, not facts
Daewoong Pharmaceutical will complete legal approval for manufacturing and processing advanced biopharmaceuticals and begin operating its facilities within the year.
Likely ยท Within months
Daewoong Pharmaceutical plans to expand its global bio network by linking its domestic base with overseas bases such as Indonesia.
Possible ยท Within months

It was found that 3,098 households received inappropriate discounts from 2021 to 2024 in the welfare discount operated by Korea Electric Power Corporation, and only 51,911,000 won, or 48.9% of the discounted amount of 106,095,000 won, was recovered. The main causes were death, moving, and change of contact information, with inadequate discounts for large families being the most common.

The Michelin Guide announced the '2026 Michelin Key Selection' and announced that it had awarded 1 to 2 keys to 9 Korean hotels. Four Seasons Hotel Seoul was upgraded from 1 key last year to 2 key this year, and there are no 3 key hotels in Korea yet. There are five evaluation criteria: architecture, service, individuality, value for money, and location relevance. There are 2,832 Michelin Key hotels around the world.

South Korea's overseas direct investment increased 32.3% year-on-year to $20.52 billion in Q2 2026, driven by growth in financial and communication sectors, according to the Ministry of Finance and Economy.

Saemangeum Development Corporation announced a bid on the 29th for the construction of a public sewage treatment facility with a capacity of 19,000 ใฅ per day for stable sewage treatment in Saemangeum waterside city. The project scale is KRW 105.4 billion, the construction period is a total of 37 months, including 6 months of commissioning, and candidates suitable for detailed design will be selected using a weighted method that adds 70% of the technology score and 30% of the price score.

Korea's foreign direct investment has shown an increase for four consecutive quarters, reaching $20.52 billion in the second quarter of this year, an increase of 32.3% compared to the same period last year. In particular, investment in the finance/insurance and information and communications industries led the way, and investment in the United States increased by 53.6% to $8.86 billion.

LG Electronics announced that it has begun targeting the AI data center market by unveiling its hydronic modular solution, air-cooled inverter turbo chiller, and liquid cooling solution at Data Center World Asia 2026 held in Singapore. Lee Jae-seong, head of ES Business Division, emphasized that the company will leap forward as a key partner in the global AI infrastructure market.